Oral baricitinib bests placebo in severe alopecia areata treatment
A 4 mg dose of baricitinib was associated with significant improvement compared with placebo in alopecia areata disease severity, according to a study. “Alopecia areata is an autoimmune disorder marked by disfiguring, nonscarring hair loss, and there are no therapies approved by the FDA for treatment of the disease,” Brett King, MD, PhD, of the Yale School of Medicine, told